Basilea seen up after raising 2026 guidance

By Reuters News

** Shares in Basilea BSLN.S are seen up 7% in pre-market indications after the Swiss biotech company raised its 2026 revenue and operating profit guidance

** The company now expects operating profit of CHF 115 mln (€124 mln), up from CHF 70 mln previously, and revenue of about CHF 310 mln

** Basilea also raised its cash flow target for 2026-2030 and its 2030 financial targets

** Up to the previous session's close, the stock was up 26%​ YTD

(1 euro = 0.9248 Swiss francs)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.